How Supplied:
0.1% cream, 30 g and 60 g; 0.1% gel, 30 g and 100 g
Indications and Usage:
Tazorac® Cream 0.1% is indicated for acne vulgaris. Tazorac® Gel 0.1% is indicated for mild to moderate facial acne vulgaris.
Prescribing Instructions:
Prescribing Information Instructions [PDF]
Side Effects and Contraindications:
Tazorac® is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient apprised of the potential hazard to the fetus. Warnings: Women of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when Tazorac® Cream or Gel 0.1% is used. Precautions: Retinoids should not be used on eczematous skin, as they may cause severe irritation. Tazorac® Cream or Gel 0.1% should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity. Patients must be warned to use sunscreens (minimum SPF 15) and protective clothing when using Tazorac® Cream and Gel 0.1%. Concomitant dermatologic agents that have a strong drying effect should be avoided. Adverse Events: The most frequent adverse reactions reported during clinical trials with Tazorac® Cream 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, dry skin, erythema, and burning sensation. The most frequent adverse events reported with Tazorac® Gel 0.1% in the treatment of acne occurring in 10% to 30% of patients, in descending order, included desquamation, burning/stinging, dry skin, erythema, and pruritus.
Company:
Allergan, Inc.
714-246-4500
www.tazorac.com
MyList
Drugs
